News headlines about Midatech Pharma (NASDAQ:MTP) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Midatech Pharma earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.5703474134634 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Midatech Pharma (MTP) opened at $1.07 on Thursday. The company has a current ratio of 1.62, a quick ratio of 1.49 and a debt-to-equity ratio of 0.03. Midatech Pharma has a 52 week low of $0.79 and a 52 week high of $3.27.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Midatech Pharma (MTP) Stock Price” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/01/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-midatech-pharma-mtp-share-price.html.
Midatech Pharma Company Profile
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.